Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources. The company may sell its Chinese business and its diagnoses unit, Cinco Dias reported. A spokesperson for the company declined to comment though in November Grifols said it was committed to reducing its 9.4 billion net debt.
Spanish pharmaceutical company Grifols reported a 30% drop in nine-month net profit on Tuesday, due in part to acquisition costs. Grifols said it was still on track to meet its full-year financial targets, but its shares fell 4.2% in morning trade. The company, which uses blood plasma to make medicines, saw its business severely hit by the pandemic as blood collection was halted in many countries.
Spanish pharma group Grifols said on Friday a lawsuit filed in the United States by blood donors who claim the company violated their privacy would have no material impact, after a report in newspaper El Economista sent the shares sharply lower. The company said about 54,000 donors in Illinois had filed a lawsuit claiming Grifols breached data protection regulations, confirming the newspaper report. Grifols shares were down 5.3% on Friday morning, briefly the worst performer on the blue-chip Ibex-35 index, which was down 2.1%.